- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Ruxolitinib in Glucocorticoid Refractory Chronic Graft versus Host Disease ; volume:42 ; number:06 ; year:2021 ; pages:582-583
Indian journal of medical & paediatric oncology ; 42, Heft 06 (2021), 582-583
- Contributor
-
Sharma, Aparna
Sharma, Vibhor
- DOI
-
10.1055/s-0041-1740950
- URN
-
urn:nbn:de:101:1-2022021710515179151027
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:38 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Sharma, Aparna
- Sharma, Vibhor
Other Objects (12)
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Role of microglia in neurological side effects of cancer immunotherapies and of ruxolitinib in steroid-refractory gastrointestinal graft versus host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Role of microglia in neurological side effects of cancer immunotherapies and of ruxolitinib in steroid-refractory gastrointestinal graft versus host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis
Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease: A Giant Leap-To Start with Baby Steps
Ruxolitinib in steroid refractory graft-vs.-host disease: a case report
Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease
Ruxolitinib for steroid-refractory chronic graft-versus-host disease: Japanese subgroup analysis of REACH3 study
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience
Ruxolitinib in steroid-refractory acute graft-vs-host disease: Japanese subgroup analysis of the randomized REACH2 trial
Compassionate use of ruxolitinib in acute and chronic graft versus host disease refractory both to corticosteroids and extracorporeal photopheresis
Effect of ruxolitinib on the oral mucosa of patients with steroid-refractory chronic Graft-versus-Host disease and oral involvement
Role of microglia in neurological side effects of cancer immunotherapies and of ruxolitinib in steroid-refractory gastrointestinal graft versus host disease
Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis